Literature DB >> 18844223

Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication.

Efstathios Kastritis1, Samuel Murray, Fani Kyriakou, Maria Horti, Nicolaos Tamvakis, Nicolaos Kavantzas, Efstratios S Patsouris, Aphrodite Noni, Sofia Legaki, Meletios A Dimopoulos, Aristotle Bamias.   

Abstract

Wnt pathway signaling is crucial in many cancers and data indicate crosstalk with other key cancer pathways, however in urothelial carcinogenesis it has not been extensively studied. We searched for mutations in adenomatous polyposis coli (APC), a key regulator of the pathway, and studied b-catenin expression and interactions with the expression of other markers of apoptosis, angiogenesis, and proliferation in patients with invasive urothelial cancer. The mutation cluster region of APC was directly sequenced in 70 patients with muscle invasive disease who were treated with surgery and adjuvant chemotherapy. COX-2, p53, Ki67, and b-catenin were studied immunohistochemically and micro vessel density was quantified by CD105 expression. Single somatic amino-acid substitutions (missense) were found in 9 (13%) and frameshift deletions in 2 (3%) tumors, all located in regions adjacent to b-catenin binding sites. Patients having either APC missense mutations or b-catenin nuclear accumulation had less frequent COX-2 overexpression (24% vs. 76%, p = 0.043) and more frequent lymph node involvement (75% vs. 38%, p = 0.023). Patients with either APC mutations or b-catenin accumulation had shorter disease-free interval (13.4 vs. 28 months, p = 0.07), whereas in multivariate analysis they had shorter disease-specific survival (60.5 vs. 20.6 months, p = 0.048). Somatic APC missense mutations are not rare in advanced urothelial neoplasms. Either APC mutations and/or aberrant expression of b-catenin are associated with worse outcome. Further study of the role of the Wnt pathway, potential crosstalk with other pathways and potential candidate therapeutic targets in urothelial cancer is needed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18844223     DOI: 10.1002/ijc.23917

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  29 in total

1.  The role of WNT signalling in urothelial cell carcinoma.

Authors:  I Ahmad
Journal:  Ann R Coll Surg Engl       Date:  2015-08-14       Impact factor: 1.891

2.  Epigenetic silencing of the dual-role signal mediator, ANGPTL4 in tumor tissues and its overexpression in the urothelial carcinoma microenvironment.

Authors:  H-Y Hsieh; Y-C Jou; C-L Tung; Y-S Tsai; Y-H Wang; C-L Chi; R-I Lin; S-K Hung; Y-M Chuang; S-F Wu; C Li; C-H Shen; M W Y Chan; C-D Hsu
Journal:  Oncogene       Date:  2017-10-16       Impact factor: 9.867

3.  High Dickkopf-1 expression is associated with poor prognosis in patients with advanced urothelial carcinoma.

Authors:  Cheng-Huang Shen; Hsiao-Yen Hsieh; Yuan-Hung Wang; Syue-Yi Chen; Chun-Liang Tung; Jiann-DER Wu; Chang-Te Lin; Michael W-Y Chan; Cheng-DA Hsu; Deching Chang
Journal:  Exp Ther Med       Date:  2010-07-21       Impact factor: 2.447

Review 4.  Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.

Authors:  Margaret A Knowles; Carolyn D Hurst
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

Review 5.  Urothelial carcinoma: stem cells on the edge.

Authors:  William D Brandt; William Matsui; Jonathan E Rosenberg; Xiaobing He; Shizhang Ling; Edward M Schaeffer; David M Berman
Journal:  Cancer Metastasis Rev       Date:  2009-12       Impact factor: 9.264

6.  β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation.

Authors:  I Ahmad; J P Morton; L B Singh; S M Radulescu; R A Ridgway; S Patel; J Woodgett; D J Winton; M M Taketo; X-R Wu; H Y Leung; O J Sansom
Journal:  Oncogene       Date:  2010-09-06       Impact factor: 9.867

7.  A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.

Authors:  Gottfrid Sjödahl; Martin Lauss; Sigurdur Gudjonsson; Fredrik Liedberg; Christer Halldén; Gunilla Chebil; Wiking Månsson; Mattias Höglund; David Lindgren
Journal:  PLoS One       Date:  2011-04-14       Impact factor: 3.240

Review 8.  Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment.

Authors:  Maria V Barbolina; Rebecca J Burkhalter; M Sharon Stack
Journal:  Biochem J       Date:  2011-07-01       Impact factor: 3.857

9.  K-Ras and β-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder.

Authors:  Imran Ahmad; Lukram Babloo Singh; Mona Foth; Carol-Ann Morris; Makoto Mark Taketo; Xue-Ru Wu; Hing Y Leung; Owen J Sansom; Tomoko Iwata
Journal:  Dis Model Mech       Date:  2011-04-18       Impact factor: 5.758

Review 10.  Messing up disorder: how do missense mutations in the tumor suppressor protein APC lead to cancer?

Authors:  David P Minde; Zeinab Anvarian; Stefan Gd Rüdiger; Madelon M Maurice
Journal:  Mol Cancer       Date:  2011-08-22       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.